2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab + Lazertinib in Atypical EGFRm Advanced NSCLC"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Byoung Chul Cho
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Byoung Chul Cho
65 views
June 14, 2024
Chapters
CHRYSALIS-2 Trial Overview & Patient Demographics
00:00
Efficacy & Safety of Amivantamab + Lazertinib
03:00
Comparative Analysis & Final Conclusions
05:47
Comments 0
Login to view comments.
Click here to Login